医薬品受託包装の世界市場-2024-2031年

概要

世界の医薬品受託包装市場は2023年に59億米ドルに達し、2031年には105億米ドルに達すると予測され、予測期間2024-2031年のCAGRは7.5%で成長する見込みです。

世界の医薬品セクターは、世界の経済成長、高齢化と人口増加、新製品の導入に後押しされ、指数関数的な速度で拡大しています。IQVIAによると、2020年の世界の医薬品市場の売上高は1兆2,652億米ドルで、着実に拡大しています。多くの製薬ベンダーは、製薬会社に商業用および臨床用の包装を委託することで収益が向上することを理解しており、そのため包装受託事業は拡大しています。

米国食品医薬品局で承認された新薬の数は、近年大幅に増加しています。例えば、米食品医薬品局によると、CDERが2020年に承認した革新的医薬品は53品目で、前年の48品目から増加しました。さらに、ジェネリック医薬品プログラムは今年、948件のジェネリック医薬品申請を承認または条件付き承認しました。FDAがより多くの革新的医薬品を承認したことで、市場はプラスの影響を受けています。

2023年には、欧州が世界の医薬品受託包装市場の約1/4を占めると予想されています。EUの規制では、すべての製薬企業がEUで医薬品を販売する場合、EUの適正製造基準（GMP）に従うことが義務付けられています。2021年1月、Novartisはドラッグデリバリーの新興企業Credence MedSystemsに戦略的投資を行いました。この投資は、Credenceのドラッグデリバリーシステムの開発と拡張性を促進することを目的としています。

ダイナミクス

注射薬の需要増加

注射薬の需要の高まりは、製薬業界におけるガラス瓶の拡大を加速させています。がん治療薬やその他の高薬理活性医薬品（抗体結合体、ステロイド、即効性のある輸液など）の市場が健全であることが、主な成長要因として期待されています。さらに、糖尿病患者の増加が注射剤用ガラス瓶の成長に大きく寄与しています。

世界保健機関（WHO）によると、糖尿病患者は世界で4億2,200万人を超えています。この数字の変化はペニシリンの需要を高め、市場の成長に貢献しています。さらに、生物製剤の成長は地域市場に大きな影響を与えると予想されます。例えば、2021年4月、Catalentはインディアナ州ブルーミントンの施設で生物製剤の包装能力を増強するために1,400万米ドルの拡張工事を完了しました。

先進包装技術

包装機械や包装材料における技術的進歩は、世界の医薬品受託包装市場の形成に貢献しています。自動化、材料科学、持続可能性における革新に後押しされた新興国市場の開拓は、大きな市場潜在機会を開くと期待されています。包装作業の自動化は技術革新の重要な要素です。

先進包装技術には、高度なロボットシステム、電子制御、リアルタイムのモニタリング機能が含まれます。これは、包装工程における精度の向上、効率の向上、人的ミスの減少につながります。例えば、2020年6月、PCI PharmaはExpericとの協力契約を発表し、臨床および商業的な製造、包装、サプライチェーンサービスを調査し、その結果、両者に総合的な成長をもたらしました。

持続可能性と代替への懸念

ライフスタイルの動向や文化の発展により消費者の嗜好が変化し、医薬品包装の需要に影響を与える可能性があります。市場浸透率が高く、顧客の嗜好が成熟しているため、先進国の医薬品受託包装事業は飽和状態にあります。メーカーは飽和した市場で製品の差別化を図り、競争に打ち勝つことが難しくなり、価格圧力や利益率の低下を招く可能性があります。

消費者は移動性、断熱性、利便性などの利点からこれらの代替品を選択するため、従来のセラミック製やガラス製の医薬品受託包装の需要が減少しています。環境の持続可能性に対する懸念の高まりにより、消費者は従来の医薬品包装に代わる環境に優しい包装を求めるようになっています。その結果、リサイクルや生分解が可能な選択肢が望まれており、非持続可能なタイプに依存している製造業者にとっては課題となっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 注射剤需要の増加
    • 先進包装技術
  • 抑制要因
    • 持続可能性と代替への懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 タイプ別

• 一次包装システム
• 二次包装システム
• 三次包装システム

第8章 原材料別

• プラスチック・ポリマー
• ガラス
• 金属
• 紙・板紙
• ゴム
• 綿
• その他

第9章 用途別

• 経粘膜ドラッグデリバリー包装
• 経肺ドラッグデリバリー包装
• 経鼻ドラッグデリバリー用包装材
• 局所ドラッグデリバリー包装
• 注射用包装
• 経口ドラッグデリバリー包装
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Catalent Pharma Solutions
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Aphena Pharma Solutions
• ROPACK INC
• Wasdell Packaging Group
• Baxter BioPharma Solutions
• AbbVie Contract Manufacturing
• Pfizer CentreSource
• Daito Pharmaceutical
• Nipro Corporation
• Becton Dickinson & Company

第13章 付録

Overview

Global Contract Pharmaceutical Packaging Market reached US$ 5.9 billion in 2023 and is expected to reach US$ 10.5 billion by 2031, growing with a CAGR of 7.5% during the forecast period 2024-2031.

The global pharmaceutical sector is expanding at an exponential rate, propelled by global economic growth, an aging and growing population and new product introductions. According to IQVIA, the globally pharmaceutical market's revenue in 2020 was US$ 1,265.2 billion and is expanding steadily. Many pharmaceutical vendors understood that outsourcing commercial and clinical packaging to a pharmaceutical contractor boost earnings, hence the contract packaging in the business is expanding.

The number of new pharmaceuticals approved by U.S. Food and Drug Administration has increased significantly in recent years. For example, the Food and Drug Administration said that CDER approved 53 innovative medications in 2020, up from 48 the previous year. Additionally, the generic medication program authorized or conditionally approved 948 generic medicine applications this year. The market has been positively impacted by the FDA's approval of more innovative medications.

In 2023, Europe is expected to be hold about 1/4th of the global contract pharmaceutical packaging market. EU regulations require all pharmaceutical firms to follow EU Good Manufacturing Practices if they want to sell their medicines in the EU. In January 2021, Novartis made a strategic investment in drug delivery startup Credence MedSystems. The investment is intended to help advance the development and scalability of Credence's drug delivery systems.

Dynamics

Increasing Demand for Injectable Pharmaceuticals

The growing demand for injectable medications is accelerating the expansion of glass bottles in the pharmaceutical industry. The healthy market for cancer and other high-potency medications (such as antibody conjugates, steroids and IV fluids with a rapid beginning of action) is expected to be the primary growth driver. Furthermore, the growing number of diabetics contributes significantly to the growth of glass bottles for injectable medications.

In accordance with the World Health Organization, over 422 million people globally have diabetes. Changes in this figure enhance demand for penicillin, contributing to market growth. Furthermore, the growth of biologics is anticipated to have a substantial impact on the regional market. For example, in April 2021, Catalent completed a US$ 14 million expansion to increase biologics packaging capacity at its Bloomington, Indiana facility.

Technological Advancements in Packaging

Technological improvements in packaging machinery and materials have helped to shape the globally contract pharmaceutical packaging market. The developments, driven by innovations in automation, materials science and sustainability, are expected to open up significant market potential opportunities. Automating packing operations is an important component of technological innovation.

Modern packaging technology includes advanced robotic systems, electronic controls and real-time monitoring capabilities. It translates into increased precision, efficiency and fewer human errors in the packing process. For example, in June 2020, PCI Pharma announced a cooperation deal with Experic to investigate clinical and commercial manufacturing, packaging and supply chain services, resulting in collective growth for both parties.

Sustainability and Alternative Concerns

Consumer tastes may shift due to growing lifestyle trends and cultural developments, affecting contract pharmaceutical packaging demand. Owing to the high market penetration and mature client preferences, the contract pharmaceutical packaging business in industrialized countries has become saturated. Manufacturers may find it difficult to differentiate their products and compete in saturated markets, resulting in pricing pressures and decreased profit margins.

Consumers choose these alternatives because of benefits such as mobility, insulation and convenience, which reduces demand for traditional ceramic or glass contract pharmaceutical packaging. Growing concerns about environmental sustainability have driven consumers to look for eco-friendly alternatives to traditional contract pharmaceutical packagings. As a result, there is a desire for recyclable and biodegradable options, which poses a challenge to producers who rely on non-sustainable types.

Segment Analysis

The global contract pharmaceutical packaging market is segmented based on type, raw material, application and region.

Lightweigth and Not Prone to Breakage Drives the Segment Growth

Plastics & polymer is expected to be the dominant segment with over 30% of the market during the forecast period 2024-2031. Plastic bottle filling will be expected to increase rapidly over the projection period due to its several benefits, including its light weight, which saves space and transportation, as well as freight costs. Unlike medications contained in glass bottles, plastic bottles are less likely to break and contribute to the necessary cost savings associated with glass bottles.

For example, Aphena Pharma Solutions, a pharmaceutical contract packaging company, said in January 2021 that it had built ten high-speed bottling lines, leveraging a US$ 21 million investment in solid dose contract packaging. The company also wants to add 30 more high-speed lines in its newly purchased 500,000 sq ft facility, increasing the monthly capacity to over 80 million bottles to target the pharmaceutical solid dose packaging market.

Geographical Penetration

Rising Investments in Pharmaceutical Sector in North America

North America is the dominant region in the global contract pharmaceutical packaging market covering more than 35% of the market. The presence of multiple pharmaceutical contract packaging service providers in the region increased the overall market size. Many contract packaging companies have made investments in extending their facilities and customer base, as well as increasing their geographical footprint, through acquisitions and collaborations.

In September 2020, Essentra Packaging revealed the acquisition of a 3C! Packaging, a North Carolina-based company that designs and manufactures cartons, literature, labels and packaging for the pharmaceutical sector. Such acquisitions allow companies like Essentra Packaging to strengthen their position in the pharmaceutical packaging industry and create prospects for growth in the pharmaceutical manufacturing hub in North America.

Competitive Landscape

The major global players in the market include Catalent Pharma Solutions, Aphena Pharma Solutions, ROPACK INC, Wasdell Packaging Group, Baxter BioPharma Solutions, AbbVie Contract Manufacturing, Pfizer CentreSource, Daito Pharmaceutical, Nipro Corporation and Becton Dickinson & Company.

COVID-19 Impact Analysis

The pandemic caused an increase in demand for pharmaceutical products such as vaccinations, drugs and medical equipment to battle the spread of COVID-19 and treat affected people. The rising demand for pharmaceuticals necessitated the use of contract packaging services to assure the timely packaging and distribution of important medicines. Regulatory authorities introduced temporary regulatory flexibilities and expedited approval processes to support the development, manufacturing and distribution of COVID-19 vaccines and treatments.

Contract packaging facilities took steps to guarantee staff safety and well-being while continuing operations during the pandemic. To reduce the danger of COVID-19 transmission, it includes creating remote labor arrangements, increased hygiene controls and social distancing measures within production facilities.

Russia-Ukraine War Impact

Russia and Ukraine are both major actors in the global pharmaceutical supply chain, supplying raw materials, active pharmaceutical ingredients and packaging materials to pharmaceutical producers globally. Any supply chain disruptions caused by the conflict, like transportation disruptions, export prohibitions or trade restrictions, may have an impact on the availability and pricing of pharmaceutical packaging materials.

The dispute interrupts the manufacture and export of vital pharmaceutical packaging materials such as polymers, plastics, glass vials and aluminum foils, causing global shortages and price instability. Contract packaging companies may experience difficulty in procuring necessary packaging materials, affecting their capacity to execute orders and meet the demand of pharmaceutical clients.

By Type

• Primary Packaging System
• Secondary Packaging System
• Tertiary Packaging System

By Raw Material

• Plastic & Polymers
• Glass
• Metals
• Paper & Board
• Rubber
• Cotton
• Others

By Application

• Transmucosal Drug Delivery Packaging
• Pulmonary Drug Delivery Packaging
• Nasal Drug Delivery Packaging
• Topical Drug Delivery Packaging
• Injectable Packaging
• Oral Drug Delivery Packaging
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In December 2022, Nelipak Corporation constructed a cutting-edge flexible packaging production facility in Winston-Salem, North Carolina. The strategic initiative will expand Nelipak's healthcare packaging capabilities across Europe to the Americas, catering to the region's growing need.
• In October 2022, Aphena Pharma Solutions Inc. reported that its US$ 20 million expansion and renovation, which began in mid-2019 in Cookeville, Tennessee, has now completed, providing a considerable amount of available solid dose packaging capacity.
• In October 2020, Alnylam Pharmaceuticals collaborated with Sharp to package its authorized RNAi therapeutic medicines for European markets. Sharp's Hamont-Achel facility in Belgium is going to handle the packaging for Alnylam's offerings throughout Europe. The agreement represented a significant foreign investment for Alnylam in Belgium, identifying with their objective to strengthen their presence in the region and establish it as a vital hub for operations.

Why Purchase the Report?

• To visualize the global contract pharmaceutical packaging market segmentation based on type, raw material, application and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of contract pharmaceutical packaging market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global contract pharmaceutical packaging market report would provide approximately 62 tables, 61 figures and 193 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1.Methodology and Scope

• 1.1.Research Methodology
• 1.2.Research Objective and Scope of the Report

2.Definition and Overview

3.Executive Summary

• 3.1.Snippet by Type
• 3.2.Snippet by Raw Material
• 3.3.Snippet by Application
• 3.4.Snippet by Region

4.Dynamics

• 4.1.Impacting Factors
  • 4.1.1.Drivers
    • 4.1.1.1.Increasing Demand for Injectable Pharmaceuticals
    • 4.1.1.2.Technological Advancements in Packaging
  • 4.1.2.Restraints
    • 4.1.2.1.Sustainability and Alternative Concerns
  • 4.1.3.Opportunity
  • 4.1.4.Impact Analysis

5.Industry Analysis

• 5.1.Porter's Five Force Analysis
• 5.2.Supply Chain Analysis
• 5.3.Pricing Analysis
• 5.4.Regulatory Analysis
• 5.5.Russia-Ukraine War Impact Analysis
• 5.6.DMI Opinion

6.COVID-19 Analysis

• 6.1.Analysis of COVID-19
  • 6.1.1.Scenario Before COVID-19
  • 6.1.2.Scenario During COVID-19
  • 6.1.3.Scenario Post COVID-19
• 6.2.Pricing Dynamics Amid COVID-19
• 6.3.Demand-Supply Spectrum
• 6.4.Government Initiatives Related to the Market During Pandemic
• 6.5.Manufacturers Strategic Initiatives
• 6.6.Conclusion

7.By Type

• 7.1.Introduction
  • 7.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2.Market Attractiveness Index, By Type
• 7.2.Primary Packaging System*
  • 7.2.1.Introduction
  • 7.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3.Secondary Packaging System
• 7.4.Tertiary Packaging System

8.By Raw Material

• 8.1.Introduction
  • 8.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 8.1.2.Market Attractiveness Index, By Raw Material
• 8.2.Plastic & Polymers*
  • 8.2.1.Introduction
  • 8.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3.Glass
• 8.4.Metals
• 8.5.Paper & Board
• 8.6.Rubber
• 8.7.Cotton
• 8.8.Others

9.By Application

• 9.1.Introduction
  • 9.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2.Market Attractiveness Index, By Application
• 9.2.Transmucosal Drug Delivery Packaging*
  • 9.2.1.Introduction
  • 9.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3.Pulmonary Drug Delivery Packaging
• 9.4.Nasal Drug Delivery Packaging
• 9.5.Topical Drug Delivery Packaging
• 9.6.Injectable Packaging
• 9.7.Oral Drug Delivery Packaging
• 9.8.Others

10.By Region

• 10.1.Introduction
  • 10.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2.Market Attractiveness Index, By Region
• 10.2.North America
  • 10.2.1.Introduction
  • 10.2.2.Key Region-Specific Dynamics
  • 10.2.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1.U.S.
    • 10.2.6.2.Canada
    • 10.2.6.3.Mexico
• 10.3.Europe
  • 10.3.1.Introduction
  • 10.3.2.Key Region-Specific Dynamics
  • 10.3.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1.Germany
    • 10.3.6.2.UK
    • 10.3.6.3.France
    • 10.3.6.4.Italy
    • 10.3.6.5.Russia
    • 10.3.6.6.Rest of Europe
• 10.4.South America
  • 10.4.1.Introduction
  • 10.4.2.Key Region-Specific Dynamics
  • 10.4.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1.Brazil
    • 10.4.6.2.Argentina
    • 10.4.6.3.Rest of South America
• 10.5.Asia-Pacific
  • 10.5.1.Introduction
  • 10.5.2.Key Region-Specific Dynamics
  • 10.5.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1.China
    • 10.5.6.2.India
    • 10.5.6.3.Japan
    • 10.5.6.4.Australia
    • 10.5.6.5.Rest of Asia-Pacific
• 10.6.Middle East and Africa
  • 10.6.1.Introduction
  • 10.6.2.Key Region-Specific Dynamics
  • 10.6.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Raw Material
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.Competitive Landscape

• 11.1.Competitive Scenario
• 11.2.Market Positioning/Share Analysis
• 11.3.Mergers and Acquisitions Analysis

12.Company Profiles

• 12.1.Catalent Pharma Solutions*
  • 12.1.1.Company Overview
  • 12.1.2.Product Portfolio and Description
  • 12.1.3.Financial Overview
  • 12.1.4.Key Developments
• 12.2.Aphena Pharma Solutions
• 12.3.ROPACK INC
• 12.4.Wasdell Packaging Group
• 12.5.Baxter BioPharma Solutions
• 12.6.AbbVie Contract Manufacturing
• 12.7.Pfizer CentreSource
• 12.8.Daito Pharmaceutical
• 12.9.Nipro Corporation
• 12.10.Becton Dickinson & Company

LIST NOT EXHAUSTIVE

13.Appendix

• 13.1.About Us and Services
• 13.2.Contact Us